Chemotherapy in Advanced Breast Cancer

References

• Abeloff M. D., Ethnger D. S. Treatment of metastatic breast cancer with Adriamycin-cyclophosphamide induction followed by alternating combination therapy. Cancer Treat. Rep. 1977; 61: 1685
   PubMedGoogle Scholar
• Ahmann D. L. M., Bisel H. F., Hahn R. G., et al. Analysis of a multiple-drug program in the treatment of patients with advanced breast cancer utilizing 5-fluorouracil, cyclophosphatide and prednisone with or without vicristine. Cancer (Phila.) 1975; 36: 1925
   PubMedGoogle Scholar
• Armand J. P., Hurteloup P., Mauriac L., et al. Phase III chemotherapy comparing FAC vs. FEC in advanced breast cancer. Preliminary results. Abstract. Satellite symposia. ECCO, Stockholm. 1985
   Google Scholar
• Band P. R., Tormev D. C., Bauer M. Induction chemotherapy and maintenance chemo-hormontherapy in metastatic breast cancer. Proc. Amer. Assoc. Cancer Res. 1977; 18: 228
   Google Scholar
• Baum M., Priestman T., West R. R., Jones E. M. A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast. Breast cancer. Experimental and clinical aspects, H. T. Mouridsen, T. Palshof. Pergamon Press, Elmsford 1980; 223–226
   Google Scholar
• Blumenschein G. R., Hortobagyi G. N., Richman S. P., et al. Alternating non-cross resistant combination chemotherapy and active non-specific immunotherapy with BCG or MER-BCG for advanced breast carcinoma. Cancer 1980; 45: 742
   PubMedGoogle Scholar
• Bonnadonna G., Valagussa B. S. Chemotherapy of breast cancer. Current views and results. Int. J. Radiat. Oncol. Biol. Phys. 1983; 9: 279
   PubMedGoogle Scholar
• Brambilla C., de Lena M., Rossi A., Valagussa P., Bonadonna G. Response and survival in advanced breast cancer after two non-cross-resistant combinations. Brit. Med. J. 1976; 1: 801
   PubMedGoogle Scholar
• Valgussa P., Bonnadonna G. Sequential combination chemotherapy in advanced breast cancer. Cancer Chemother. Pharmacol. 1978; 1: 35
   PubMedGoogle Scholar
• Brincker H., Axelsen F. New techniques for intravenous access and prolonged infusions relevant to new doxorubicin dosage schedules. Antracyclines and cancer therapy, J. H. Hansen. Excerpta Medica, Amsterdam 1982; 186
   Google Scholar
• Broder L. E., Tormey D. C. Combination chemotherapy of carcinoma of the breast. Cancer Treat. Rev. 1974; 1: 183
   Google Scholar
• Bull J. M., Tormey D. C., Li S.-H., et al. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 1978; 41: 1649
   PubMed Web of Science ®Google Scholar
• Anderson T., Lippman M. E., Cassidy J. G., Gormley P. E., Young R. C. A phase II trial of cis-dichlorodam-mine platinum (cis-DDP) in breast and ovarian carcinomas. AACR Abstracts 1978; 345
   Google Scholar
• Byrne P. J. A randomized multi-centre trial of cyclophosphamide, mitoxantrone and 5-fluorouracil (CNF) vs. cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Third European Conference on Clinical Oncology and Cancer Nursing. (Abstract.) Stockholm. 1985
   Google Scholar
• Carbone P. P., Bauer P., Tormey D. Chemotherapy of disseminated breast cancer. Current status and prospects. Cancer 1977, Suppl. No. 39: 2916
   PubMedGoogle Scholar
• Carter S. K. Chemotherapy of breast cancer. Current status. Breast cancer. Trends in research and treatment, J. C. Heuson, W. H. Mattheim, M. Rosencweig. Raven Press, New York 1976; 193
   Google Scholar
• Casazza A. M. Advances in anthracycline chemotherapy. Epirubicin, G. Bonnadonna. Masson, Milano 1984
   Google Scholar
• Cavalli F., Pedrazzini A., Mastz G., et al. Randomized trial of 3 different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment for advanced breast cancer. Europ. J. Cancer Clin. Oncol. 1983; 19: 1615
   PubMedGoogle Scholar
• Chlebowski R. Adriamycin (Doxorubicin) cardiotoxicity. A review. West. J. Med. 1979; 131: 364
   PubMedGoogle Scholar
• Pugh R., Weiner J. M., Block J. B., Bateman J. R. Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer. A randomized trial. Cancer 1983; 52: 606
   Google Scholar
• Smalley R., Weiner J., et al. Combination (comb) vs. sequential single agent (seq) chemotherapy in advanced breast cancer. Relationship between survival and metastatic site. Proc. AACR and ASCO 1979; 20: 436
   Google Scholar
• Cooper R. G. Combination chemotherapy in hormone resistant breast cancer. Proc. Amer. Assoc. Cancer Res. 1969; 10: 15
   Web of Science ®Google Scholar
• Cortes Funes H., Ruiz M. J., Manas A., Vallejo C., Cabezas M. A., Nieto A. Adriamycin given weekly for the treatment of advanced breast cancer patients. Third European Conference on Clinical Oncology and Cancer Nursing (Abstract No. 627.) Stockholm. 1985
   Google Scholar
• Creech R. H., Catalano R. B., Harris D. T., Engstrom P. F., Grotzinger P. J. Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrezate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin. Cancer 1979; 43: 51
   PubMedGoogle Scholar
• Hopson R. C. A comparison of standard dose adriamycin (SDA) and low dose adriamycin (LDA) as primary chemotherapy for metastatic breast cancer. Proc. Amer. Assoc. Cancer Res. 1980; 21: 142
   Google Scholar
• Shah M. K. An effective low-dose adriamycin regimen as secondary chemotherapy for metastatic breast cancer patients. Cancer 1980; 46: 433
   PubMedGoogle Scholar
• Fischer J., Rose C. J., Rubens R. D. Duration of complete response to chemotherapy in advanced cancer. Europ. J. Cancer Clin. Oncol. 1982; 18: 747
   PubMedGoogle Scholar
• Forastiere A. A., Hakes T. B., Wittes J. I. Cisplatin in the treatment of metastatic breast carcinoma. Amer. J. Clin. Oncol. 1982; 5: 243
   PubMed Web of Science ®Google Scholar
• Glick J. H., Creech R. H., Torri S., et al. Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer. Breast Cancer Res. Treat. 1981; 1: 59
   PubMedGoogle Scholar
• Goldie J. H., Coldman A. J. A mathematical model for relating the drugs sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 1979; 63: 1727
   PubMedGoogle Scholar
• Greenspan E. M. Combination cytotoxic chemotherapy in advanced disseminated breast cancer. J. Mt Sinai Hosp. 1966; 33: 1
   PubMedGoogle Scholar
• Gundersen S. A randomized trial of high dose medroxypro-gesterone-acetete in addition to chemotherapy for ER negative advanced breast cancer patients. (Abstract.) Nordisk Radioterapikongress, Malmo. 1984
   Google Scholar
• Kvinnsland S., Klepp O., Kvaloy S. Weekly adriamycin versus AC in advanced breast cancer. Europ. J. Cancer Clin. Oncol. 1986; 22: 1431
   PubMedGoogle Scholar
• Gyves J., Ensminger W., Niederhuber J., et al. Totally implanted system for intravenous chemotherapy in patients with cancer. Amer. J. Med. 1982; 73: 841
   PubMedGoogle Scholar
• Hayward J. L., Carbone P. P., Heuson J.-C, Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer. Cancer 1977; 39: 1289
   PubMed Web of Science ®Google Scholar
• Henderson I. C. Chemotherapy of breast cancer. A general overview. Cancer 1983; 51: 2553
   Google Scholar
• Wolff S., Allegra J., et al. Mitoxantrone vs. doxorubicin in advanced breast cancer. A randomized trial in 220 patients. Third European Conference on Clinical Oncology and Cancer Nursing. (Abstract.) Stockholm. 1985
   Google Scholar
• Henningsen B., Linder F., Steichele C. Endocrine treatment of breast cancer. A new approach, B. Henningsen, F. Linder, C. Steichele. Springer-Verlag, Berlin, Heidelberg, New York 1980
   Google Scholar
• Hoogstraten B., George S. L., Samal B., et al. Combination chemotherapy and adriamycin in patients with advanced breast cancer, A Southwest Oncology Group Study. Cancer 1976; 38: 13
   PubMed Web of Science ®Google Scholar
• Hurley J. O., Trump D. S., Flateley T. J., Reisch J. D. A method of selecting patients for cancer chemotherapy. Arch. Surg. 1961; 83: 143
   Google Scholar
• Karnofsky D. A., Abelman W. H., Craver L. F., Burchenal J. H. The use of nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948; 1: 634
   Web of Science ®Google Scholar
• Kiang D. T., Kennedy B. J. Chemoendocrine therapy of advanced breast cancer. Breast Cancer Res. Treat. 1981; 1: 105
   PubMedGoogle Scholar
• Kvaloy S., Gundersen S., Fosså S. D., Eliassen G., Sjølie I., Høst H. Vincristine, Adriamycin, Cyclophosphamide (VAC) vs. Prednumustine, Methotrexate, 5-FU (PMF) in advanced breast cancer. A randomized phase IV study. Third EORTC breast cancer working conference. (Abstract.). 1983
   Google Scholar
• Kvinnsland S., et al. A phase II study. 5-FU and Mitomycin-C in advanced breast cancer. Third European Conference on Clinical Oncology and Cancer Nursing. (Abstract.) Stockholm. 1985
   Google Scholar
• Kolaric K., Roth A. Phase II clinical trial of cis-dichlor-odiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother. Pharmacol. 1983; 11: 108
   PubMed Web of Science ®Google Scholar
• Korsten G. B., Engelsman E., Persijn J. P. Clinical value of estrogen receptors in advanced breast cancer. Estrogen receptors in human breast cancer, W. L. McGuire, P. P. Carbone, E. P. Vollmer. Raven Press, New York 1974; 93–105
   Google Scholar
• Leung S. B., Moseley H. S., Davenport C. E., Krippaehne W. W., Fletcher W. S. Estrogen receptor in prediction of clinical response to endocrine ablation. Estrogen receptors in human breast cancer, W. L. McGuire, P. P. Carbone, E. P. Vollmer. Raven Press, New York 1974; 107
   Google Scholar
• Lippman M. E., Cassidy J., Wesley M., Young R. C. A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization (Abstr C-305). Proc. Amer. Soc. Clin. Oncol. 1982; 1: 79
   Google Scholar
• McGuire W. L., Carbone P. P., Sears M. E., Escher G. C. Estrogen receptors in human breast cancer. An overview. Estrogen receptors in human breast cancer, W. L. McGuire, P. P. Carbone, E. P. Vollmer. Raven Press, New York 1975; 1
   Google Scholar
• Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207
   PubMed Web of Science ®Google Scholar
• Mouridsen H. T., Palshof T., Engelsman E., Sylvester R. CMF versus CMF plus Tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial. Breast cancer. Experimental and clinical aspects, H. T. Mouridsen, T. Palshof. Pergamon Press, Oxford 1980; 119
   Google Scholar
• Muss H. B., White D. R., Richards F., et al. Adriamycin vs methotrexate in five-drug combination chemotherapy for advanced breast cancer. A randomized trial. Cancer 1978; 42: 2141
   Google Scholar
• Niederhuber J. E., Ensminger W., Gyves J. W., Liepman M., Doan K., Cozzi E. Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery 1982; 92: 706
   PubMed Web of Science ®Google Scholar
• Ozols R. F., Cowan K. New aspects of clinical drug resistance. The role of gene amplification and the reversal of resistance in drug refractory cancer. Important advances in oncology 1986, V. T. De Vita, Jr, S. Hellman, S. A. Rosenberg. J. B. Lippincott, Philadelphia 1986
   Google Scholar
• Patel J. K., Nemoto T., Vezeridis M., Petrelli N., Suh O., Dao T. Does more intensive palliative treatment improve overall survival in metastatic breast cancer patients?. Cancer 1986; 57: 567
   PubMed Web of Science ®Google Scholar
• Paterson A. H. G., Szafran O., Cornish F., Lees A. W., Hanson J. Effect of chemotherapy on survival in metastatic breast cancer. Breast Cancer Res. and Treat. 1981; 1: 357
   PubMedGoogle Scholar
• Pellegrini A., Robustelli Della Cuna G., Estevez R., et al. Vincristine, adriamycin cyclophosphamide (VAC) vs. vincristine, adriamycin, cyclophosphamide plus high dose medrocyprogesterone acetate (VAC + HD MPA). A randomized multinational clinical trial in metastatic breast cancer. Proc. XIII Intl. Cancer Congress. (Abstract 01629.), Seattle, 1982
   Google Scholar
• Powles T. J., Smith I. E., Ford H. T., Coombes R. C., Mary Jones J., Gazet J.-C. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet 1980; I: 580
   Google Scholar
• Price P., Hoskin P. J., Easton D., Austin D., Palmer S. G., Yarnold J. R. Prospective randomized trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother. Oncol. 1986; 6: 247
   PubMed Web of Science ®Google Scholar
• Smalley R. V., Carpenter J., Bartolucci A., Vogel C., Krauss S. A comparison of cyclophosphamide, Adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: A Southwestern Cancer Study Group Project. Cancer 1977; 40: 625
   PubMed Web of Science ®Google Scholar
• Murphy S., Huguley C. M., Jr, Bartolucci A. Combination versus sequential five-drug chemo-therapy in metastatic carcinoma of the breast. Cancer Res. 1976; 3911
   PubMedGoogle Scholar
• Starkhammar H., Bengtsson M. Totally implanted device for venous access. Acta Radiol. Oncology 1985; 24: 173
   PubMed Web of Science ®Google Scholar
• Steiner R., Stewart J. F., Cantwell B. M., Minton M. J., Knight R. K., Rubens R. D. Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Europ. J. Cancer Clin. Oncol. 1983; 19: 1553
   PubMedGoogle Scholar
• Swenerton K. D., Legha S. S., Smith T., et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res. 1979; 39: 1552
   PubMed Web of Science ®Google Scholar
• Todd M., Shoag M., Cadman E. Survival of women with metastatic breast cancer at Yale from 1920 to 1980. J. Clin. Oncol. 1983; 1: 406
   PubMed Web of Science ®Google Scholar
• Tormey D. C., Carbone P., Band P. Breast cancer survival in single and combination chemotherapy trials since 1968. Proc. Amer. Assoc. Cancer Res. 1977; 18
   Google Scholar
• Falkson G., Simon R. M., et al. A randomized comparison of two sequentially administered combination regimens to a single regimen in metastatic breast cancer. Cancer Clin. Trials 1979; 2: 247
   Google Scholar
• Tucker W. G., Talley R. W., Lane M., et al. Treatment of adenocarcinoma with combination of cyclophosphamide (NSC-26271), vincristine (NSC-67574), and 5-fluorouracil (NSC-1983). Cancer Chemother. Rep. 1975; 59: 425
   PubMedGoogle Scholar
• Valdmeso M., Burgess M. A., Ewer M. S., et al. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer. A prospective, randomized study. J. Clin. Oncol. 1984; 2: 207
   PubMedGoogle Scholar
• Weiss A. J., Metter G. E., Fletcher W. S., Wilson W. L., Grage T. B., Ramirez G. Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat. Rep. 1976; 60: 813
   PubMedGoogle Scholar
• Manthel R. W. Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer 1977; 40: 2046
   PubMedGoogle Scholar
• Yap H. H., Salem P., Hortobagyi G. N., et al. Phase II study of cis-dichloro-diammineplatinum (II) in advanced breast cancer. Cancer Treat. Rep. 1978; 62: 405
   PubMedGoogle Scholar
• Yarbro J. W., Bornstein R. S., Mastrangelo M. J. New perspectives in chemotherapy. Focus on Novantrone. Sem. Oncol. 1984, Suppl. No. 1
   Google Scholar
• Yuong R. C., Chabner B. A., Ozols R. F., Hamilton T. C., Devita V. T., Jr. Evolution in treatment strategy with growth-inhibiting drugs. Clinical trials in cancer medicine. Past achievements and future prospects, U. Veronesi, G. Bonadonna. Academic Press, New York 1985; 203
   Google Scholar